SLC5A2 and diabetes mellitus: SGLT2 inhibitors, a novel class of drug used for treatment of diabetes, increase urinary glucose excretion by inhibiting the major glucose transporter in the kidney, SGLT2, thereby controlling the blood glucose level [1].